890-P: Durability of Continuous Glucose Monitoring (CGM) Use in Young Children, Teens, and Young Adults with Type 1 Diabetes (T1D)
2020
Use of CGM can optimize glycemic control; however, consistency of CGM use in youth and teens/young adults with T1D has been low in prior studies. We assessed 1-year use of Dexcom CGM in young children (ages 2 to Disclosure D. DeSalvo: Consultant; Self; Dexcom, Inc., Insulet Corporation. L. Kanapka: None. C. Bauza: None. C. Xie: None. L. DiMeglio: None. L.M. Laffel: Advisory Panel; Self; Roche Diabetes Care. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Insulogic LLC, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi US. K. Miller: None. Funding The Leona M. and Harry B. Helmsley Charitable Trust; Dexcom, Inc.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI